CN111909107B - IDO/HDAC dual inhibitor and pharmaceutical composition and application thereof - Google Patents
IDO/HDAC dual inhibitor and pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN111909107B CN111909107B CN201910387782.1A CN201910387782A CN111909107B CN 111909107 B CN111909107 B CN 111909107B CN 201910387782 A CN201910387782 A CN 201910387782A CN 111909107 B CN111909107 B CN 111909107B
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- heterocyclic
- acid
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
sample | IC 50 (μM) |
INCB24360 | 0.055 |
I | 0.043 |
II | 0.046 |
III | 0.033 |
IV | 0.039 |
V | 0.021 |
VI | 0.032 |
VII | 0.018 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910387782.1A CN111909107B (en) | 2019-05-10 | 2019-05-10 | IDO/HDAC dual inhibitor and pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910387782.1A CN111909107B (en) | 2019-05-10 | 2019-05-10 | IDO/HDAC dual inhibitor and pharmaceutical composition and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111909107A CN111909107A (en) | 2020-11-10 |
CN111909107B true CN111909107B (en) | 2023-02-03 |
Family
ID=73242190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910387782.1A Active CN111909107B (en) | 2019-05-10 | 2019-05-10 | IDO/HDAC dual inhibitor and pharmaceutical composition and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111909107B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113105366B (en) * | 2021-03-04 | 2022-05-24 | 中国药科大学 | Phenyl-containing hydroximic structure derivatives, and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101212967A (en) * | 2005-05-10 | 2008-07-02 | 因塞特公司 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
CN106866571A (en) * | 2017-01-20 | 2017-06-20 | 中国药科大学 | Heterocyclic urea compound and its pharmaceutical composition and application |
CN108003111A (en) * | 2017-12-14 | 2018-05-08 | 华东理工大学 | Double target spot inhibitor of a kind of HDAC1 and IDO1 and its preparation method and application |
WO2019057123A1 (en) * | 2017-09-20 | 2019-03-28 | 杭州英创医药科技有限公司 | Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor |
-
2019
- 2019-05-10 CN CN201910387782.1A patent/CN111909107B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101212967A (en) * | 2005-05-10 | 2008-07-02 | 因塞特公司 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
CN106866571A (en) * | 2017-01-20 | 2017-06-20 | 中国药科大学 | Heterocyclic urea compound and its pharmaceutical composition and application |
WO2019057123A1 (en) * | 2017-09-20 | 2019-03-28 | 杭州英创医药科技有限公司 | Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor |
CN108003111A (en) * | 2017-12-14 | 2018-05-08 | 华东理工大学 | Double target spot inhibitor of a kind of HDAC1 and IDO1 and its preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
CN111909107A (en) | 2020-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2908823B1 (en) | Methods of treating cancer | |
Vicini et al. | Synthesis and antiproliferative activity of benzo [d] isothiazole hydrazones | |
Winum et al. | Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines | |
US20100081654A1 (en) | Oncogenic-RAS-signal dependent lethal compounds | |
US8232410B2 (en) | Benzimidazoles and pharmaceutical compositions thereof | |
Buza et al. | Discovery of novel benzenesulfonamides incorporating 1, 2, 3-triazole scaffold as carbonic anhydrase I, II, IX, and XII inhibitors | |
CN103054869A (en) | Application of amino dithio formic ester compound with triazolyl in preparing medicine taking LSD1 (Lysine Specificity Demethylase 1) as target | |
Li et al. | Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans | |
Durgun et al. | Synthesis, characterization, in vitro cytotoxicity and antimicrobial investigation and evaluation of physicochemical properties of novel 4-(2-methylacetamide) benzenesulfonamide derivatives | |
CA2928468A1 (en) | Novel dgat2 inhibitors | |
Cincinelli et al. | Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity | |
CN102260190A (en) | N-benzyl-N'-(terminal carboxylic acid substituted acyloxy)octanediamide compounds with anti-tumor effect and pharmaceutical salts thereof | |
US20200165257A1 (en) | Inhibitors of phosphoinositide 3-kinase and histone deacetylase for treatment of cancer | |
CN111909107B (en) | IDO/HDAC dual inhibitor and pharmaceutical composition and application thereof | |
US9695181B2 (en) | Hydroximic acid derivatives and medical applications therof | |
US7999000B2 (en) | N-(2-amino-phenyl)-acrylamides | |
EP2313412B1 (en) | Novel derivatives of pyrroloindole inhibitors of hsp90, compositions containing same, and use thereof | |
CN108299255B (en) | Histone deacetylase 8 selective inhibitor and preparation method and application thereof | |
CN102746213A (en) | Cinnamamide histone deacetylase inhibitor, preparation method thereof, and application thereof | |
CN109851614B (en) | Heterocyclic peptide deformylase inhibitor and preparation method and application thereof | |
CN108530337B (en) | Indoleamide compound capable of selectively inhibiting gastric cancer cells | |
US10266489B2 (en) | Pyrrolic amide compound and preparation method and application thereof | |
CN113527195B (en) | 5-aryl nicotinamide LSD1/HDAC double-target inhibitor, preparation method and application thereof | |
CN114539237B (en) | IDO inhibitor, preparation method, pharmaceutical composition and application | |
Batra et al. | Synthesis and antibacterial evaluation of novel sulfonamide based [1, 2, 3]-triazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210809 Address after: 100036 Beijing city Haidian District Cuiwei Road No. 2, building A, room 1209, static source in Applicant after: Beijing Kexiang Zhongsheng Pharmaceutical Technology Co.,Ltd. Address before: No. 639 Jiangning longmian Road District of Nanjing City, Jiangsu province 211198 Applicant before: CHINA PHARMACEUTICAL University |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210819 Address after: 224500 4th floor, North building, building 2, enterprise accelerator, Xin'an Avenue, Binhai Pharmaceutical Industrial Park, Binhai County, Yancheng City, Jiangsu Province Applicant after: Yaokang Zhongtuo (Jiangsu) Pharmaceutical Technology Co.,Ltd. Address before: 100036 Beijing city Haidian District Cuiwei Road No. 2, building A, room 1209, static source in Applicant before: Beijing Kexiang Zhongsheng Pharmaceutical Technology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230317 Address after: Room 628, 6th Floor, Building 2, Yard 30, Jinxing Road, Daxing District, Beijing, 100023 Patentee after: Yaokang Zhongtuo (Beijing) Pharmaceutical Technology Co.,Ltd. Address before: 224500 4th floor, North building, building 2, enterprise accelerator, Xin'an Avenue, Binhai Pharmaceutical Industrial Park, Binhai County, Yancheng City, Jiangsu Province Patentee before: Yaokang Zhongtuo (Jiangsu) Pharmaceutical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right |